Research
Hormonal
Obesity acts as a chronic systemic low-grade inflammation where adipose tissue and its hormones play a central role, linking obesity to insulin resistance and NAFLD.
Managing body fat is not just about weight; it is about reducing the inflammatory signal sent by fat tissue to the liver and pancreas, which is a primary driver of fatty liver disease.
GoodSupportsHIGH confidence
Obesity, which is often associated with IR, is therefore often seen as a chronic systemic low-grade inflammation, in which adipose tissue and its hormones have a central role.
Why this rating
Supported by numerous references [21-23] and consistent findings across human and animal studies.
Source
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease
Sanja Stojsavljević · World Journal of Gastroenterology · 2014
DOI 10.3748/wjg.v20.i48.18070
narrative_reviewCited 320×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adiponectin, des-acyl ghrelin, and leptin are adipokines that decrease insulin resistance and subsequently nonalcoholic fatty liver disease (NAFLD), whereas proinflammatory cytokines TNF-α and IL-6 enhance insulin resistance and promote NAFLD.Moderate
- Leptin levels are elevated in obesity and NASH, correlating with hepatic steatosis severity, but leptin resistance may prevent its protective anorectic effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →